• New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple
solid tumour indications from the combination of eftilagimod alpha (“efti”) and avelumab (BAVENCIO®)
• Expansion into urothelial cancer builds…
Mesa Laboratories, Inc. (NASDAQ:MLAB) (“we”, “Mesa” or the “Company”), a global leader in the design and manufacturing of critical quality control solutions for the pharmaceutical, healthcare, and medical device industries, today announced the…
Christiane von der Eltz was appointed to the Executive Board of BERLIN-CHEMIE on June 1 of this year and is responsible for the Pharma Germany division. The qualified pharmacist brings with her a wealth of experience in the pharmaceutical industry.…
The glass ceiling in the healthcare sector in the capital region is getting thinner. More and more women are finding their way into leadership positions. In order to reduce the inequalities that still exist further, stakeholders in the healthcare…
Takeda, the global biopharmaceutical company, has a history of more than 240 years rich in tradition and always characterized by further development and innovation. In Germany, however, the focus of Takeda is not only on shaping progress in the…
After two years of intensive renovation work, the new location of Charité BIH Innovation (CBI) - the joint technology transfer of Charité and BIH - has opened on October 12. Covering a total of 2,500 m2 spread over four floors, the modern, expanded…
Reverse Clinical Engineering® is now available to oncologists and cancer patients in Saudi Arabia, the Middle East, and North Africa. ASC Oncology proudly announces new partnership with Tamer Group.
Targenomix, a spin-off of the Max Planck Institute for Molecular Plant Physiology, will contribute to Bayer’s Crop Science R&D pipeline by continuing to deliver novel systems biology approaches for innovative crop protection discovery / Targenomix…
Berlin/Aalborg, 27 October 2022. The University Hospital Aalborg (Denmark) yesterday has imaged the first patient with Eckert and Ziegler’s Gallium (68Ga) boclatixafortide (PENTIXAFOR) in an international phase 2 trial.
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with MAGE-A1 positive solid tumors
TK-8001 targets a MAGE-A1 epitope presented on HLA-A*02:01
IMAG1NE…
